![Thomas Gidoin](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Thomas Gidoin
Direttore Finanziario/CFO presso
OSE IMMUNOTHERAPEUTICS
Profilo
Thomas Gidoin is Chief Financial Officer & Deputy CEO at OSE Immunotherapeutics SA since 2026.
Formerly, Controller at Ipsen SA from 2008 to 2011, Vice President-Finance at DBV Technologies SA from 2012 to 2015, and Chief Financial Officer at Gensight Biologics SA from 2015 to 2024.
Education includes graduate degrees from Ecole Supérieure de Gestion et Finances and NEOMA Business School.
Posizioni attive di Thomas Gidoin
| Società | Posizione | Inizio |
|---|---|---|
| OSE IMMUNOTHERAPEUTICS | Direttore Finanziario/CFO | 20/08/2025 |
Precedenti posizioni note di Thomas Gidoin
| Società | Posizione | Fine |
|---|---|---|
| GENSIGHT BIOLOGICS S.A. | Direttore Finanziario/CFO | 26/01/2024 |
| DBV TECHNOLOGIES | Direttore Finanziario/CFO | 01/01/2015 |
| IPSEN | Comptroller/Controller/Auditor | 01/01/2011 |
Formazione di Thomas Gidoin
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
65
Relazioni di 1° grado
6
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 6 |
|---|---|
Ipsen SA
 Ipsen SA Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
DBV Technologies SA
 DBV Technologies SA Pharmaceuticals: MajorHealth Technology Operates as a clinical stage biopharmaceutical company that focuses on changing the field of immunotherapy | Health Technology |
Ecole Supérieure de Gestion et Finances
 Ecole Supérieure de Gestion et Finances Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Gensight Biologics SA
 Gensight Biologics SA Pharmaceuticals: MajorHealth Technology Manufactures and markets novel therapies for severe retinal neurodegenerative diseases | Health Technology |
NEOMA Business School
 NEOMA Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
OSE Immunotherapeutics SA
 OSE Immunotherapeutics SA Pharmaceuticals: MajorHealth Technology Develops immunotherapy products for late-stage cancers | Health Technology |
